Pre-B-cell colony enhancing factor expression and its clinical significance in colorectal cancer

doi:10.3760/cma.j.issn.1673422X.2016.12.004

Abstract

Abstract: ObjectiveTo explore the expression of preBcell colony enhancing factor (PBEF) in colorectal cancer, and analyze the relationship between PBEF expression and the clinical pathological characteristics and its diagnostic and prognostic value. MethodsSixtyeight human colorectal tumor and normal colorectal tissues were collected, and the expression of PBEF was detected by immunohistochemical method. The relationship between the expression level of PBEF and the characteristics of tumors and prognosis was analyzed. ResultsThe positive expression rate of PBEF in colorectal cancer tissues was 80.9%, higher than that in normal colorectal tissues, which was 29.4% (χ2=36.41, P<0.05). The expression level of PBEF had no relationship with age (χ2=0.11, P>0.05), sex (χ2=0.39, P>0.05), histology type (χ2=0.54, P>0.05) or penetrating serosa (χ2=1.55, P>0.05), but significantly associated with the degree of differentiation (χ2=6.29, P<0.05), metastasis of lymph node (χ2=4.32, P<0.05), distant metastasis (χ2=4.16, P<0.05) and clinical stage (χ2=7.58, P<0.05). The 5 year survival rates of patients with positive and negative expression of PBEF were 73.3% and 81.8%, and the difference was not statistically significant (χ2=0.315, P>0.05). ConclusionThe abnormal high expression of PBEF may be closely related to the occurrence and development of colorectal cancer.

Key words: Colorectal neoplasms, Immunohistochemistry, Pre-B-cell colony enhancing factor

ZHANG Zhi-Jin, FU Jun, ZHANG Yu-Hao, GE Cui-Cui, QIN Xian-Ju. Pre-B-cell colony enhancing factor expression and its clinical significance in colorectal cancer[J]. Journal of International Oncology, 2016, 43(12): 896-899.

References

［1］ Pavlova T, Novak J, BienertovaVasku J. The role of visfatin (PBEF/Nampt) in pregnancy complications［J］. J Reprod Immunol, 2015, 112: 102110. DOI: 10.1016/j.jri.2015.09.004. ［2］ He JY, Tu C, Li MJ, et al. Nampt/visfatin/PBEF: a functionally multifaceted protein with a pivotal role in malignant tumors［J］. Curr Pharm Des, 2012, 18(37): 61236132. ［3］ Romacho T, SánchezFerrer CF, Peiró C. Visfatin/nampt: an adipokine with cardiovascular impact［J］. Mediators Inflamm, 2013, 2013: 946427. DOI: 10.1155/2013/946427. ［4］ Sonoli SS, Shivprasad S, Prasad CV, et al. Visfatina review［J］. Eur Rev Med Pharmacol Sci, 2011, 15(1): 914. ［5］ Ding YH, Zhou ZW, Ha CF, et al. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells［J］. Drug Des Devel Ther, 2015, 9: 425464. DOI: 10.2147/DDDT.S74062. ［6］ Huang R, Wang ZR, Sun Y, et al. Mechanism of Nampt gene expression regulation［J］. Yi Chuan, 2012, 34(12): 15611569. ［7］ Sun ZJ, Lei H, Zhang ZE. PreB cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions［J］. Cytokine Growth Factor Rev, 2013, 24(5): 433442. DOI: 10.1016/j.cytogfr.2013.05.006. ［8］ Astern JM, Collier AC, KendalWright CE. PreB cell colony enhancing factor (PBEF/NAMPT/Visfatin) and vascular endothelial growth factor (VEGF) cooperate to increase the permeability of the human placental amnion［J］. Placenta, 2013, 34(1): 4249. DOI: 10.1016/j.placenta.2012.10.008. ［9］ Yin H, Van Der Veer E, Frontini MJ, et al. Intrinsic directionality of migrating vascular smooth muscle cells is regulated by NAD(+) biosynthesis［J］. J Cell Sci, 2012, 125(23): 57705780. DOI: 10.1242/jcs.110262. ［10］ Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer［J］. Cancer Biol Ther, 2010, 10(2): 119125. DOI: 10.4161/cbt.10.2.12581. ［11］ Ke HL, Lin HH, Li WM, et al. High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients［J］. Am J Cancer Res, 2015, 5(8): 24472454.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[8]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Liao Lihua, Wang Shaohong, Chen Hongcai, Zhao Yongqiang. Value of cell paraffin block immunohistochemistry and pleural effusion CRKL and MIC-1 in the diagnosis of malignant pleural effusion [J]. Journal of International Oncology, 2023, 50(2): 71-75.
[10]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[11]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[12]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[13]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[14]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.
[15]	Zhao Ying, Zhang Gehong. Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer [J]. Journal of International Oncology, 2022, 49(8): 473-477.